, Volume 52, Issue 7, pp 1240–1249

Melatonin receptors in pancreatic islets: good morning to a novel type 2 diabetes gene


    • Unit of Molecular Metabolism, Department of Clinical Sciences in MalmöLund University Diabetes Centre
  • C. L. F. Nagorny
    • Unit of Molecular Metabolism, Department of Clinical Sciences in MalmöLund University Diabetes Centre
  • V. Lyssenko
    • Unit of Diabetes and Endocrinology, Department of Clinical Sciences in Malmö, Lund University Diabetes Centre, Clinical Research CenterMalmö University Hospital
  • L. Groop
    • Unit of Diabetes and Endocrinology, Department of Clinical Sciences in Malmö, Lund University Diabetes Centre, Clinical Research CenterMalmö University Hospital

DOI: 10.1007/s00125-009-1359-y

Cite this article as:
Mulder, H., Nagorny, C.L.F., Lyssenko, V. et al. Diabetologia (2009) 52: 1240. doi:10.1007/s00125-009-1359-y


Melatonin is a circulating hormone that is primarily released from the pineal gland. It is best known as a regulator of seasonal and circadian rhythms; its levels are high during the night and low during the day. Interestingly, insulin levels also exhibit a nocturnal drop, which has previously been suggested to be controlled, at least in part, by melatonin. This regulation can be explained by the proposed inhibitory action of melatonin on insulin release. Indeed, both melatonin receptor 1A (MTNR1A) and MTNR1B are expressed in pancreatic islets. The role of melatonin in the regulation of glucose homeostasis has been highlighted by three independent publications based on genome-wide association studies of traits connected with type 2 diabetes, such as elevated fasting glucose, and, subsequently, of the disease itself. The studies demonstrate a link between variations in the MTNR1B gene, hyperglycaemia, impaired early phase insulin secretion and beta cell function. The risk genotype predicts the future development of type 2 diabetes. Carriers of the risk genotype exhibit increased expression of MTNR1B in islets. This suggests that these individuals may be more sensitive to the actions of melatonin, leading to impaired insulin secretion. Blocking the inhibition of insulin secretion by melatonin may be a novel therapeutic avenue for type 2 diabetes.


AANATBeta cellCircadianCLOCKGenome-wide associationInsulinMetabolismSNPSuprachiasmatic nucleus



Arylalkylamine N-acetyltransferase


Inhibitory G protein


HOMA of beta cell function


Melatonin receptor 1A


Phospholipase C


Protein kinase A


Single nucleotide polymorphism


The recent advent of the genome-wide association studies of type 2 diabetes and its associated traits has proved to be a tremendous breakthrough in diabetes and metabolic research [1, 2]. These studies have produced lists of genes, many of which were not suspected to be associated with the disease, to which the research field now needs to shift its attention. The great majority of these genes appear to be mainly implicated in beta cell function. In this review, we describe the unexpected discovery that a well-known hormone—melatonin—which has previously been implicated in the control of seasonal and circadian rhythms may be an important player in the events leading to the development of type 2 diabetes. To place this discovery into context, we will briefly outline the principles of biological rhythm, summarise the biology of melatonin—a key component of the system—and describe what is known about the link between melatonin, its receptors, and the pathogenesis of type 2 diabetes.

Chronobiology, metabolic control and disease

It was realised as far back as in the eighteenth century that organisms, ranging from unicellular to multicellular, exhibit inherent rhythms. Such rhythmicity plays an important role in the temporal control of a wide range of biological processes in the body, the most notable of which is metabolism [3].

Biological rhythms

The most important and well-known biological rhythm is the circadian rhythm. The name is derived from the Greek words for around (circa) and day (diem), and is defined as the roughly 24 h cycle that characterises virtually all organisms on Earth. It is an adaptation to the periodicity at which our planet moves around its axis, which determines day length. In addition to circadian rhythm, there are ultradian rhythms, which are shorter than 24 h, and infradian rhythms, which extend beyond 24 h. To be considered a circadian rhythm, three major criteria must be fulfilled: (1) it should persist under constant external conditions, i.e. endogenously generated; (2) it should be temperature-insensitive; (3) it can be reset by an external stimulus, i.e. entrainment.

Control of circadian rhythm

Tremendous advances have been made in recent years in the understanding of how circadian rhythms are controlled [3]. A complex of the transcription factors referred to as circadian locomotor output cycles kaput (CLOCK) and brain and muscle aryl hydrocarbon receptor nuclear translocator (ARNT)-like 1 (BMAL1) controls the Period (PER) genes. This offsets oscillating feedback loops of transcription and translation, which generate waves of gene expression with a periodicity of 24 h. While this machinery is endogenously generated, it is entrained by external stimuli, of which light is perhaps the most critical one. It is also sensitive to signals from metabolism, e.g. cellular redox state has been shown to affect CLOCK activity [4]. The system is hierarchical, the suprachiasmatic nucleus in the hypothalamus being the ‘master clock’, with additional clock activities in numerous peripheral tissues. In fact, there is some evidence for a circadian rhythm in pancreatic islets [5]. The peripheral clocks are all thought to signal back to the ‘master clock’ in the suprachiasmatic nucleus.

Disruption of circadian rhythm and metabolic disease

Given the intimate relationship between circadian rhythms and metabolism, a link between the disruption of circadian rhythm and metabolic perturbation has been considered [3]. Indeed, the metabolic syndrome is more prevalent in shift workers [6], known to exhibit disturbances of circadian rhythm, and sleep-deprivation has been associated with both obesity and type 2 diabetes [7]. Moreover, when circadian rhythm is experimentally misaligned in humans, a profound effect on both plasma insulin and glucose levels, promoting glucose intolerance, is observed [8].


The hormone melatonin is an integral part of the homeostatic mechanisms in the body. It signals whether light or dark prevails. Melatonin is a critical ‘zeitgeber’, i.e. a cue entraining clock mechanisms in various parts of the body. In this capacity, many of the effects of melatonin can be sought.

Structure and synthesis

Melatonin, like the neurotransmitter serotonin, is an indoleamine. It is converted in two steps from the amino acid tryptophan into serotonin (5-hydroxytryptamine, 5-HT), and then acetylated by arylalkylamine N-acetyltransferase (AANAT), the rate-limiting step in melatonin biosynthesis, before finally being converted into melatonin by hydroxyindole-O-methyl transferase [9].

Localisation of melatonin

The hormone is mainly secreted by endocrine cells (pinealocytes) in the pineal gland, which is located in the midline of the brain, just above the posterior commissure at the dorsal edge of the third ventricle. Melatonin remains detectable after pinealectomy in some species [10], and subsequent investigations revealed that the hormone is produced by neuroendocrine cells in the retina, Harderian glands, gastrointestinal tract and pancreas [11]. Melatonin is also produced by numerous non-endocrine cells, e.g. immune cells. Hence, while the pineal gland quantitatively accounts for the circulating pool of the hormone, substantial local synthesis also occurs in retina and peripheral tissues such as the gastrointestinal tract.

Pineal secretion of melatonin

Because melatonin is stored neither in large dense core nor small synaptic vesicles in the pineal gland [12], melatonin is released constitutively [13], the rate of release being determined by the rate of synthesis. The synthesis and subsequent secretion of melatonin are, in most species, regulated by the activity of AANAT. This control is exerted at both the transcriptional and post-translational level, the relative importance of these processes in control being species-dependent.

Central to the control of these processes is stimulation of β1-adrenergic receptors by noradrenergic input to the pineal gland. This is mainly derived from the superior cervical ganglion, which receives signals from the retina via the suprachiasmatic and paraventricular nuclei in the hypothalamus. In addition, a plethora of inputs that employ the same pathway, as well as circulating transmitters and hormones, are integrated and affect the function of the pinealocytes and the release of melatonin [14].

The β1-adrenergic receptors in the pineal gland activate the protein kinase A (PKA)/cAMP signalling pathway [14]. An important downstream effect of this pathway is the inhibition of the proteasomal degradation of AANAT [15]; this effect appears to be particularly important in humans. It explains why there is actually a very modest daily variation in AANAT mRNA levels in humans, but a prominent rhythm of protein levels and activity. Moreover, PKA phosphorylates the transcription factor cAMP-responsive element binding protein, which activates transcription of AANAT; this process is particularly effective in rodents, in which, at night, there is an approximately 100-fold increase in pineal gland levels of AANAT mRNA [16]. Furthermore, AANAT is itself subject to phosphorylation by PKA, which enhances its activity [15].

Light entrains the circadian clock, making melatonin production occur during night. Because the onset and offset of melatonin secretion are controlled by the clock, moving closer together in the summer and further apart in winter, the duration of melatonin production varies according to the time of year [17, 18]. However, in the absence of light and in blind people, a circadian rhythm of melatonin secretion persists, and in these cases cycle length is governed by the suprachiasmatic nucleus [19]. Exposure to light at night also has an acute suppressive effect on melatonin production. In rodents, exposure to light at night decreases melatonin within minutes, while mRNA levels for the protein remain high for hours. The withdrawal of noradrenergic input to the pineal gland leads to a loss of the inhibition of proteasomal degradation, and hence light causes the AANAT protein to be rapidly degraded.

These considerations have led to the following model (Fig. 1) for how melatonin is released from the pineal gland [16, 2022]: the circadian clock in the suprachiasmatic nucleus is more active during the day than at night. The neurons in the suprachiasmatic nucleus release γ-aminobutyric acid (GABA) to inhibit the activity of neurons in the paraventricular nucleus. These neurons drive sympathetic output through the superior cervical ganglion to the pineal gland. At night, neuronal activity in the suprachiasmatic nucleus decreases, and the paraventricular neurons are disinhibited. Consequently, the noradrenergic input to the pineal gland from the superior cervical ganglion increases. The subsequent β-adrenergic stimulation leads to an increase in the synthesis and release of melatonin because of increased levels and activity of AANAT. Circulating levels of melatonin peak at ∼200 pg/ml in the middle of the night and drop to ∼10 pg/ml during day time; the half-life of the hormone in the circulation is less than 20 min [20].
Fig. 1

Regulation of melatonin release from the pineal gland. The circadian clock in the suprachiasmatic nucleus (SCN) is controlled by retinal photoreceptors activated by light. During night time, the noradrenergic (NE) input to the pineal gland from the superior cervical ganglion (SCG) increases. Activation of β1-adrenergic receptors (β1-AR) coupled to stimulatory G proteins (Gs) subsequently activates adenylate cyclase (AC), leading to an increase in cellular cAMP levels. Protein kinase A (PKA) becomes activated. This results in the inhibition of the ubiquitin proteasomal system (UPS), which, when active, degrades serotonin-N-acetyl transferase (AANAT), which catalyses the rate-limiting step in melatonin biosynthesis. In addition, PKA phosphorylates and activates the cAMP-responsive element binding protein (CREB), which leads to transcriptional activation of the gene encoding AANAT. The AANAT protein is also phosphorylated and activated by PKA. All these processes, albeit to variable degrees in different species, increase the activity of AANAT and, hence, increase the rate of synthesis and release of melatonin. The dotted lines indicate that steps have been omitted. aa, amino acids; act., activation; 5-HT, 5-hydroxytryptamine (i.e. serotonin); mel, melatonin

Physiological effects of melatonin

The most well-known role of melatonin is that as a chronobiotic factor or ‘zeitgeber’, adjusting the timing or reinforcing oscillations of the biological clock, i.e. entrainment [20]. As such, it is thought to participate in the control of seasonal as well as circadian rhythms. This is based on the fact that the secretion of melatonin reflects ambient light and normally exhibits a tightly regulated diurnal pattern—for this reason melatonin is sometimes called ‘the hormone of darkness’. Disruptions may occur in individuals deprived of light, e.g. shift workers or travellers across time zones. On a daily basis, melatonin has a small modulatory effect on the pacemaker activity of the circadian clock in the suprachiasmatic nucleus. On a seasonal basis, the varying lengths of the peaks and troughs of the circulating levels of melatonin follow the changes in the duration of daylight. The seasonal regulation of the nocturnal secretory duration is the primary cue regulating reproductive function in mammals that breed seasonally.

Melatonin also affects the cardiovascular system [23] and interacts with the immune system [24]. It has also been implicated in metabolic control [25]. Given that the sites of melatonin production are widespread, effects may be both endocrine, via melatonin released from the pineal gland, and paracrine/autocrine, via melatonin released in the vicinity of its target tissues [26].

An interesting feature of melatonin is its capacity to act as an antioxidant, owing to its chemical structure. However, melatonin does not undergo redox cycling, i.e. repeated oxidation and reduction, but is instead a terminal or suicidal antioxidant [27].

Pharmacological use of melatonin

The phase-advancing effects of melatonin have frequently been exploited [28], with the hormone proven to be effective in the treatment of insomnia [29, 30] and efficient in limiting jet lag when travelling across time zones [31]. The administration of melatonin promotes both phase advancement and resynchronisation of the biological clock.

Melatonin receptors

Structure of melatonin receptors

There is a family consisting of three melatonin receptor subtypes that belong to the class of G protein-coupled receptors [32]; two functional melatonin receptors are found in mammals. The human gene names MTNR1A and MTNR1B correspond to Mel1a (or MT1) and Mel1b (or MT2) receptors, respectively, in rodents.

Signal transduction of melatonin

Melatonin inhibits the accumulation of cAMP [33, 34] and exerts most of its effects in a pertussis toxin-sensitive fashion [35]. This implies that the melatonin receptor(s) is coupled to an inhibitory G protein (Gi); however, a cholera toxin-sensitive action has also been observed [36], indicating coupling to G0. The most prominent response to melatonin receptor occupation is inhibition of adenylate cyclase, leading to a fall in cellular cAMP levels [32]. Melatonin receptor 1A (MTNR1A), but possibly not MTNR1B, also affects phospholipase C (PLC) activity, promoting the formation of inositide phosphates and arachidonic acid [37], and possibly diacylglycerol. MTNR1B, but not 1A, has been shown to inhibit formation of cGMP, via the soluble guanylate cyclase pathway [38]. In vitro, MTNR1A associates with Gi2 and Gi3, which results in the inhibition of adenylate cyclase, and Gq/11, which activates the PLC pathway [39, 40].

Distribution of melatonin receptors

The great majority of melatonin receptors are found in the brain [32]. MTNR1A is vastly more abundant than MTNR1B. In most species, MTNR1A mRNA is found in the suprachiasmatic and paraventricular nuclei of the hypothalamus, and the pars tuberalis of the pituitary. Mtnr1b mRNA occurs in the suprachiasmatic nucleus and the hippocampus in rodents; it has also been detected in human retina and brain.

Melatonin and glucose homeostasis

Circulating insulin and melatonin levels

Nocturnal levels of the anabolic hormone insulin are low—since humans are programmed not to eat during the night, there will be little need for insulin, which controls metabolism in the postprandial and anabolic states. In fact, an excess of insulin could have detrimental effects on the central nervous system if hypoglycaemia were to occur. Because melatonin is a biological signal of darkness [32] and, consequently, reduced metabolism, it has been proposed that melatonin could contribute to the nocturnal lowering of insulin in humans.

That insulin secretion is controlled by circadian mechanisms is supported by studies of humans with circadian misalignment, who are reported to show profound perturbations of plasma glucose and insulin levels [8]. The concept is supported by the assumption that there is a circadian clock in pancreatic islets [5]. While it is clear that insulin secretion exhibits a circadian rhythm, it is unclear whether secretion increases or decreases during the night [41, 42].

There are indications that the diurnal secretion of melatonin is altered in diabetes, particularly when neuropathy is evident [43]. Peschke et al. [44] reported reduced circulating levels of melatonin and elevated levels of insulin in type 2 diabetic patients, with a statistically significant negative correlation found between the two. No information on treatment or disease duration was given in this study [44], but the increased levels of insulin suggest that the patients did not suffer from advanced insulin-requiring type 2 diabetes. Similarly, nocturnal melatonin levels are reduced in the Goto–Kakizaki (GK) rat, a model of type 2 diabetes [44]. Confusingly, animal models of type 1 diabetes, i.e. streptozotocin- and alloxan-treated rodents, exhibit either elevated [45] or decreased [46] levels of melatonin. Data from rodent studies are both contradictory and difficult to interpret with respect to melatonin and metabolism, given that these species eat during the subjective night time.

Altering melatonin action in vivo

Effects of pinealectomy

One way of reducing melatonin levels in vivo is to perform a pinealectomy. For obvious reasons, this is a major perturbation, which largely abolishes circulating melatonin. Moreover, the time at which the samples are drawn also has a major effect on the outcome of the study. Experiments of this kind are therefore difficult to interpret, and, indeed, the results from many of these studies are contradictory [25]. The more recent studies suggest that the removal of melatonin by pinealectomy in rodents leads to an increase in plasma glucose levels and a decrease in plasma insulin levels [47], particularly during night time [48].

Effects of exogenous melatonin

Melatonin has been shown to inhibit insulin secretion in the rat and mouse [49]. Nevertheless, chronic administration of melatonin ameliorates metabolic perturbations in Otsuka Long–Evans Tokushima Fatty rats, including hyperinsulinaemia [50]; it is unclear whether this is a direct or indirect effect, and whether melatonin acts in this way under physiological conditions. These seemingly inconsistent results could be attributed to different time courses for melatonin administration; clearly, this is of paramount importance, given the short half-life of the hormone and the requirements for rhythmicity. Also, the time of day the experiments or measurements are performed would profoundly affect the results.

Effects of insulin on melatonin

It has been argued that insulin itself controls the production and subsequent release of melatonin [25]. This argument is difficult to resolve, given the many effects induced by insulin, which secondarily may affect the pineal gland. The concept is supported by the finding of Ins mRNA in the pineal gland [45]. Indeed, both glucose and insulin reduce adrenaline (epinephrine)-induced melatonin secretion from perifused pineal glands [45]. Although it is likely that the pineal gland is exposed to circulating insulin, given that it is localised outside the blood–brain barrier [20], the identity of the cells that harbour the insulin receptor has not yet been determined.

Melatonin and insulin secretion

Melatonin receptors in pancreatic islets and beta cells

If melatonin has direct effects on insulin secretion, its receptors should be present in islets of Langerhans, preferably beta cells. This indeed appears to be the case, as inferred from studies using the non-hydrolysable GTP analogue guanosine 5′-O-(3-thiotriphosphate) and the melatonin antagonist luzindole [51], both of which block the effects of melatonin on insulin secretion from neonatal rat islets. MTNR1A mRNA was subsequently demonstrated in INS-1 cells [52, 53] and in rat [54, 55] and human islets [55]. MTNR1B mRNA has also been detected in rat [54, 55] and human islets [55], but at levels several-fold lower than those of MTNR1A mRNA. MIN-6 cells also express both forms of the receptor [55]. In human islets, MTNR1A mRNA occurs primarily in alpha cells [55], and the level of MTNR1B mRNA is lower than that of MTNR1A mRNA.

We were able to confirm that rodent and human islets contain mRNA for both types of melatonin receptor [56]. However, contrary to previous findings [54, 55], we found that the differences between the levels of the receptor mRNAs were not as big as in human islets [56]. We also observed that the MTNR1B protein predominantly occurs in beta cells in either human or rodent islets; MTNR1A protein is found in peripherally located beta cells.

Melatonin and insulin secretion

The existing literature implies that melatonin inhibits insulin secretion from pancreatic beta cells [25], although there are reports of no effect [57] or a stimulatory effect [58].

Melatonin as an inhibitor of insulin secretion in isolated islets and beta cells

Melatonin attenuates glucose- and KCl-stimulated insulin secretion from perifused rat islets [59]. The inhibitory effect of melatonin on insulin release from rat islets was later confirmed [60]. Melatonin stimulates the release of glucagon from perifused human islets [55]; insulin release was also stimulated, presumably indirectly through glucagon. The inhibitory effects of melatonin on insulin secretion have been replicated in clonal beta cells [53, 55, 56, 58].

Signal transduction of melatonin in islets and beta cells

An insulinostatic effect of melatonin is consistently observed for insulin release potentiated by agents that elevate cAMP levels (Fig. 2). This is in line with the coupling of MTNR1A and MTNR1B to Gi [32] and, indeed, it was found that melatonin is particularly effective at abrogating the potentiation of insulin secretion by forskolin [53] or glucagon-like peptide 1 [52]. Furthermore, the application of melatonin blocks the efflux of cAMP from INS-1 cells, presumably reflecting decreased formation of cAMP [53] or the activity of a cAMP-response element (CRE) construct [52]. Interestingly, prolonged pretreatment of either INS-1 cells or rat islets with melatonin potentiates the secretory response to cAMP-raising agents [52]. In contrast, melatonin does not affect cAMP levels in human islets, whereas the formation of cAMP in MIN-6 cells is impaired, as is insulin secretion in response to melatonin [55].
Fig. 2

Melatonin receptor signalling in pancreatic beta cells. Both melatonin receptors (MTNR1A and MTNR1B) are G protein-coupled receptors and are expressed in pancreatic beta cells. Both receptors are coupled to a Gi, which inactivates adenylate cyclase, and lowers cAMP levels in the cell, which results in reduced insulin secretion. This effect is mainly a result of MTNR1A signalling. MTNR1A is also coupled to a Gq, which activates PLC, cleaving phosphatidylinositol-4,5-biphosphate (PIP2) into inositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG), and the IP3 stimulates calcium release from the endoplasmic reticulum. In contrast, this signalling pathway has an enhancing effect on insulin secretion, and has been suggested to be mediated by MTNR1B as well. MTNR1B signalling inhibits cGMP formation, reducing insulin secretion in the pancreatic beta cell. PKC, protein kinase C

Activation of MTNR1B inhibits the formation of cGMP [38], and addition of melatonin to INS-1 cells decreases cellular levels of cGMP, paralleling the impairment of insulin secretion [61]. MTNR1A has also been implicated in signalling controlled by PLC [37], possibly via coupling to Gq/11 [39]. It has been reported that stimulation of INS-1 cells with melatonin provokes the release of inositol 1,4,5-triphosphate [58, 62], and when Gi coupling is blocked by pertussis toxin, a stimulatory effect of melatonin is uncovered [58].

Genome-wide association studies and MTNR1B

In view of the effects of melatonin on islets and on whole body metabolism, a link between melatonin receptors and type 2 diabetes was suggested [63] following the demonstration of increased levels of MTNR1A and MTNR1B mRNA in pancreatic tissue from patients with type 2 diabetes and increased immunolabelling of MTNR1A and MTNR1B. Although these results were qualitative rather than quantitative, it was postulated that there is a link between the melatonin system and the pathogenesis of the disease. While an association between MTNR1A and type 2 diabetes has not been confirmed in the recently performed genome-wide association studies [56, 64, 65], there is now strong support for associations of genetic variation in the MTNR1B locus with fasting glucose levels, insulin secretion and type 2 diabetes. In fact, two different single nucleotide polymorphisms (SNPs; rs1387153 and rs10830963) in MTNR1B were reported to be associated with type 2 diabetes, and there appear to be additional SNPs in this gene that show a similar association [65]. Although rs10830963 maps to within the single 11.5 kb intron of MTNR1B, it does not interfere with the binding of consensus transcription factors or with splicing [65]. Thus, it is likely that the SNPs reported to be associated with MTNR1B tag the same signal. Very recently, associations of rs10830963 with elevated fasting plasma glucose and future risk of type 2 diabetes was confirmed in a Chinese population [66].

All recently published articles on the variation in MTNR1B report an association with elevated fasting plasma glucose [56, 6466]. This appears to be accounted for by impaired beta cell function; we demonstrated that this is reduced in the early phase of insulin secretion [56], while another report indicated impaired beta cell function as assessed by HOMA (HOMA-B) [65]. Deterioration of glucose-stimulated insulin secretion over time in carriers of the risk allele was reported in the Botnia prospective study [56]. Moreover, all three reports find that variations in MTNR1B are associated with [64, 65] or predict future type 2 diabetes [56] with an odds ratio ranging between 1.09 and 1.20. This may seem a modest increase in risk, but it is, in fact, of a similar magnitude to those previously reported for other genes associated with an increased risk of type 2 diabetes. It emphasises that common type 2 diabetes is a polygenic disease, whereby each gene makes a variable, often small, contribution to the overall risk. Indeed, it has been shown that carriers of several risk variants are subject to an additive risk of developing the disease [64]. Moreover, the risk allele of MTNR1B appears to be relatively unique among genes affecting fasting plasma glucose in that it also is significantly associated with future risk of type 2 diabetes [56, 64, 65]; most of the previously described candidate genes for type 2 diabetes do not affect fasting plasma glucose, once people with subclinical diabetes are excluded from the analysis.

We demonstrated that both MTNR1B mRNA and the protein occur in human islets, predominantly beta cells [56]. This was confirmed by the finding that sorted human beta cells and islets contain identical mRNA species [64]. Clearly, the SNPs in MTNR1B that are associated with, for example, type 2 diabetes, may in themselves not be pathogenic, but, rather, serve as markers for an allele linked to the disease. However, levels of MTNR1B mRNA in islets from carriers of a GG genotype are higher in individuals older than 45 years, and a trend for increased levels of the receptor mRNA in islets from type 2 diabetic patients is also evident [56]. This strongly suggests that MTNR1B is responsible for the increased risk of type 2 diabetes in carriers of the risk allele. Ongoing sequencing of MTNR1B will hopefully reveal pathogenic sequence alterations.

Pathogenetic implications of the association between MTNR1B and type 2 diabetes

In this review we have described some aspects of the endocrine system based on melatonin, which may be relevant for the control of metabolic homeostasis and, possibly, the development of type 2 diabetes. That alterations in MTNR1B are, beyond doubt, linked to an increased risk of type 2 diabetes [56, 64, 65]—the level of statistical significance is very high—but the precise nature of the link remains to be clarified.

The work performed to date does provide some clues (Fig. 3). We described how levels of MTNR1B mRNA are increased in older carriers of the risk allele [56]. Given that most of the available data support a direct inhibitory effect of melatonin on insulin secretion [25], an at-risk individual may thus be more sensitive to the inhibitory effect of melatonin than an individual without the risk allele, who would have a normal islet level of MTNR1B. Such a restraining effect of melatonin is in line with the impairment of early phase insulin secretion [56] and reduced HOMA-B [65] observed in carriers of the risk allele. The possibility that perturbed rhythmic secretion of melatonin could contribute to disease development is intriguing and deserves further study in type 2 diabetes. Also, the effect of melatonin on insulin secretion, particularly in human islets, needs more attention. In fact, there is a well-established link between sleep disorders and risk of type 2 diabetes [67]. It will be of interest to explore whether genetic variations in MTNR1B explain this connection, at least in part. Some of the emerging scientific questions that need to be answered are given in the text box.
Fig. 3

Proposed pathogenetic mechanism for altered melatonin signalling in type 2 diabetes. In individuals carrying the risk allele (G) in MTNR1B, there is an increased level of mRNA for this subtype of melatonin receptor in pancreatic beta cells. Consequently, the effect of melatonin on the beta cell may be exaggerated, leading to a decrease in cAMP levels, since the receptor is coupled to a Gi. In the event that cAMP levels decrease in the beta cells, the insulinotropic pressure, e.g. that exerted by glucagon-like peptide 1, may be diminished. This could potentially result in a decrease in the amount of insulin secreted, and hence contribute to elevated fasting plasma glucose, lower circulating insulin levels, and the increased risk of type 2 diabetes observed in carriers of the SNPs rs10830963 and/or rs1387153


Time will tell whether MTNR1B antagonists may serve as therapeutic agents in type 2 diabetes. The option of blocking the effect of melatonin in islets is an attractive possibility. However, an islet-specific attenuation of melatonin action may be required, since it can be envisioned that the systemic effects of MTNR1B blockade may be disadvantageous. Nevertheless, the discovery of the link between MTNR1B and type 2 diabetes re-emphasises the importance of biological rhythm for metabolic regulation.


The authors thank all co-authors of the article on which we have collaborated [56], and D. R. Weaver at the University of Massachusetts Medical School, who provided feedback on this review. Work by the authors described here was supported by a Linneaus grant from the Swedish Research Council (60023701), as well as several other grants from the Swedish Research Council (to H. Mulder 14196, L. Groop 10858), an equipment grant from the Wallenberg Foundation, and by the European Foundation for the Study of Diabetes/MSD (to H. Mulder), the Crafoord and Albert Påhlsson Foundations, the Swedish Diabetes Association, and the Faculty of Medicine at Lund University.

Duality of interest

L. Groop has been a consultant and served on advisory boards for sanofi-aventis, GSK, Novartis, Merck, Tethys Bioscience and Xoma. He has received lecture fees from Lilly and Novartis. The authors declare that there is no duality of interest associated with this manuscript.

Copyright information

© Springer-Verlag 2009